Back Back
Cell No. : Cell Name
RCB1383 : TUHR14TKB  update : 2024/04/01
CommentJapanese renal carcinoma cells.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Kawai, Kouji & Ohno, Tadao
Originator Saijo, Kaoru
Year of deposit 1997
Another name NaKi
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Tissue kidney
Classification cancer
Year of origin 1997
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_5953
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/2 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
Chromosome mode 80-88(50) : /82(4),83(7),84(11),85(8),86(5),87(3)/
STR(human) OK
deposit info
lot info
Reference information Reference 0
User's Publication 21

To topTop

To topTop
User's Publication
19543  Thierry S, Maadadi S, Berton A, Dimier L, Perret C, Vey N, Ourfali S, Saccas M, Caron S, Boucard-Jourdin M, Colombel M, Werle B, Bonnin M.  TL-532, a novel specific Toll-like receptor 3 agonist rationally designed for targeting cancers: discovery process and biological characterization  Microb Cell  2023  10(6):117-132  PubMed ID: 37275475   DOI: 10.15698/mic2023.06.797
17497  Nickless A, Zhang J, Othoum G, Webster J, Inkman MJ, Coonrod E, Fontes S, Rozycki EB, Maher CA, White NM.  Pan-Cancer Analysis Reveals Recurrent BCAR4 Gene Fusions across Solid Tumors  Mol Cancer Res  2022  20(10):1481-1488  PubMed ID: 35852383   DOI: 10.1158/1541-7786.MCR-21-0775
20629  Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, Signoretti S, Kaelin WG Jr.  Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.  Proc Natl Acad Sci U S A  2022  119(14):e2120403119  PubMed ID: 35357972   DOI: 10.1073/pnas.2120403119
3741  Saleeb RM, Farag M, Lichner Z, Brimo F3, Bartlett J, Bjarnason G, Finelli A, Rontondo F, Downes MR, Yousef GM  Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.  Mol Oncol  2018  12(10):1673-1688  PubMed ID: 29896907   DOI: 10.1002/1878-0261.12346
3747  Nagao K, Shinohara N, Smit F, de Weijert M, Jannink S, Owada Y, Mulders P, Oosterwijk E, Matsuyama H.  Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.  BMC Cancer.  2018  18(1):1114  PubMed ID: 30442117   DOI: 10.1186/s12885-018-5060-8
10184  Takaoka N, Takayama T, Ozono S.  Functional analysis of fatty acid binding protein 7 and its effect on fatty acid of renal cell carcinoma cell lines.  BMC Cancer  2017  17:192  PubMed ID: 28292269   DOI: 10.1186/s12885-017-3184-x
3745  Ning Z, Yongjing L, Yunzhen W, Zichuang Y, Qiang Z, Cheng W, Zhiqiang C, Yan X.  Optimization of cell lines as tumour models by integrating multi-omics data.  Brief Bioinform  2017  18(3):545  PubMed ID: 28013237   DOI: 10.1093/bib/bbw121
3743  Ando R, Tokuda N, Yamamoto T, Ikeda K, Hashimoto N, Taguchi R, Fan X, Furukawa K, Niimura Y, Suzuki A, Goto M, Furukawa K  Immunization of A4galt-deficient mice with glycosphingolipids from renal cell cancers resulted in the generation of anti-sulfoglycolipid monoclonal antibodies.  Glycoconj J  2016  33(2):169-80  PubMed ID: 26883028   DOI: 10.1007/s10719-016-9654-6
12964  Kato T, Inoue H, Imoto S, Tamada Y, Miyamoto T, Matsuo Y, Nakamura Y, Park JH.  Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells  Oncotarget  2016  7(14):17652-64  PubMed ID: 26933922   DOI: 10.18632/oncotarget.7755
3744  Nakamura R, Oyama T, Tajiri R, Mizokami A, Namiki M, Nakamoto M, Ooi A.  Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma.  Cancer Sci  2015  106(5):656-64  PubMed ID: 25726761   DOI: 10.1111/cas.12649
3746  Li QC, Li HJ, Liu S, Liang Y, Wang X, Cui L.  Inhibition of γ-secretase by retinoic acid chalcone (RAC) induces G2/M arrest and triggers apoptosis in renal cell carcinoma.  Int J Clin Exp Pathol  2015  8(3):2400-7  PubMed ID: 26045747  
6384  Hidenori Kawashima Sakae Masaki Marie Kawamura  Induction of HLA‑A* 33‑restricted cytotoxic lymphocytes against renal cell carcinoma targeting galectin 9 and PINCH  Biomedical Reports  2014  2:809-812  PubMed ID: 25279150   DOI: 10.3892/br.2014.334
15911  Tan C, Takayama T, Takaoka N, Fujita H, Miyazaki M, Sugiyama T, Ozono S.  Impact of Gender in Renal Cell Carcinoma: The Relationship of FABP7 and BRN2 Expression with Overall Survival  Clin Med Insights Oncol  2014  8:21-7  PubMed ID: 24653654   DOI: 10.4137/CMO.S13684
3516  Takaoka N, Takayama T, Teratani T, Sugiyama T, Mugiya S, Ozono S.  Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines.  BMC Mol Biol  2011  12:31  PubMed ID: 21771320   DOI: 10.1186/1471-2199-12-31
6387  Minami K, Chano T, Kawakami T, Ushida H, Kushima R, Okabe H, Okada Y, Okamoto K.  DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma.  Clin Cancer Res  2010  16(10):2751-9  PubMed ID: 20460473   DOI: 10.1158/1078-0432.CCR-09-3338
8851  Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, Takayama T, Mugiya S, Ozono S, Nozawa R.  Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma.  Cancer Sci.  2007  98:77-82  PubMed ID: 17083565   DOI: 10.1111/j.1349-7006.2006.00355.x
3396  Yamada, Daisuke, Kikuchi, Shinji, Williams, Yuko N, Sakurai-Yageta, Mika, Masuda, Mari, Maruyama, Tomoko, Tomita, Kyoichi, Gutmann, David H, Kakizoe, Tadao, Kitamura, Tadaichi, Kanai, Yae, Murakami, Yoshinori  Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma.  Int J Cancer  2006  118:916-23  PubMed ID: 16152585   DOI: 10.1002/ijc.21450
5012  Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K.  Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.  Hum Mol Genet  2006  15(6):821-30  PubMed ID: 16439445   DOI: 10.1093/hmg/ddl001
14006  Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T, Miki T, Nakamura Y, Katagiri T.  Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma  Int J Oncol  2006  29(4):799-827.  PubMed ID: 16964377  
6450  Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T.  Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.  Oncol Rep  2004  12(4):805-10  PubMed ID: 15375503  
18700  Teratani T, Watanabe T, Kuwahara F, Kumagai H, Kobayashi S, Aoki U, Ishikawa A, Arai K, Nozawa R.  Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma  Cancer Lett  2002  175(1):71-7  PubMed ID: 11734338   DOI: 10.1016/s0304-3835(01)00724-8

Back Back Return Top Page